|
ABVD Therapy
Regimen
|
00290a
Hodgkin’s Lymphoma.
|
|
Bendamustine Monotherapy
Regimen
|
00527a
Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL)
|
|
Brentuximab vedotin Monotherapy
Regimen
|
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):
00234a
Following autologous stem cell transplant (ASCT)
or
00234b
Following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option
00234c
Treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)
00234d
Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy.
00234e
Treatment of adult patients with CD30+ Hodgkins Lymphoma (HL) at increased risk of relapse or progression following an autologous haematopoietic stem cell transplant (ASCT).
|
|
Brentuximab vedotin and Bendamustine Therapy*
Regimen
|
00529a
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)
|
|
Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP)
Regimen
|
00530a
Treatment of adult patients with relapsed/refractory CD30+ Hodgkin’s lymphoma.
|
|
Brentuximab vedotin and cycloPHOSphamide, DOXOrubicin and prednisoLONE (CHP) Therapy
Regimen
|
00801a
Brentuximab vedotin in combination with cyclophosphamide, DOXOrubicin and prednisoLONE (CHP) for use in adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
|
|
Brentuximab vedotin and ICE Therapy*
Regimen
|
00528
Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL).
|
|
Chlorambucil 10mg/m2 Therapy
Regimen
|
00411a
Treatment of patients with low grade lymphoma.
|
|
CHOEP Therapy-21 days
Regimen
|
00396a
Treatment of T-cell non-Hodgkin's Lymphoma.
|
|
Cladribine 5 day and riTUXimab Therapy
Regimen
|
00531a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia
|
|
Cladribine Weekly and riTUXimab Therapy
Regimen
|
00534a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia
|
|
Cladribine 0.14mg/day Day 1 to 5 Therapy
Regimen
|
00402a
First line treatment for adult patients with Hairy Cell Leukaemia
|
|
Cladribine 0.14mg/kg Weekly Therapy
Regimen
|
00469a
First line treatment for adult patients with Hairy Cell Leukaemia
|
|
cycloPHOSphamide 2000mg/m2 For Stem Cell Mobilisation
Regimen
|
00438a
Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy
|
|
cycloPHOSphamide 1500mg/m2 For Stem Cell Mobilisation
Regimen
|
00795a
Mobilisation of peripheral blood stem cells for future stem cell rescue following high dose chemotherapy
|
|
cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (CHOP) Therapy– 21 days
Regimen
|
00841a
Treatment of non-Hodgkin's lymphoma (NHL)
|
|
Dexamethasone, riTUXimab and Cyclophosphamide (DRC) Therapy
Regimen
|
00532a
Treatment of symptomatic treatment naive or relapsed/refractory Waldenström’s macroglobulinaemia
|
|
Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH)
Regimen
|
00355a
Treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin's lymphoma (NHL).
|
|
Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R(S/C) EPOCH) Therapy
Regimen
|
00672a
Treatment of patients with CD20 positive diffuse large B-cell non-Hodgkin’s lymphoma (NHL)
|
|
ESHAP Therapy
Regimen
|
00838a
Treatment of relapsed non-Hodgkin's Lymphoma
00838b
Treatment of relapsed Hodgkins Lymphoma
|
|
Escalated Dose BEACOPP 21 day Therapy
Regimen
|
00354a
Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)
00354b
Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD
|
|
Escalated Dose BEACOPDAC 21 Day Therapy
Regimen
|
00837a
Treatment of patients with high risk, advanced stage Hodgkin Lymphoma (IPS ≥ 3)
00837b
Escalation of treatment of patients with Hodgkin Lymphoma after failure to reach complete metabolic response post 2 cycles of ABVD
|
|
Ibrutinib Therapy-CLL Waldenström’s macroglobulinaemia
Regimen
|
00296a
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
00296b
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
00296c
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
|
|
Ibrutinib Therapy (Mantle Cell Lymphoma)
Regimen
|
00297a
As a single agent for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
|
|
Idelalisib Monotherapy
Regimen
|
00291a
Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.
|
|
Mogamulizumab Therapy
Regimen
|
00761a
As monotherapy for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy
|
|
High dose Methotrexate, high dose Cytarabine, riTUXimab and Thiotepa (MATRix)Therapy
Regimen
|
00508a
Treatment of primary CNS lymphoma
00508b
Treatment of CNS relapse of a high grade systemic lymphoma
|
|
Nivolumab 240mg Monotherapy - 14 Day
Regimen
|
00483c
As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
|
|
Nivolumab 480mg-28days
Regimen
|
00484d
As monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.
|
|
Nordic Therapy Protocol
Regimen
|
00393a
Mantle Cell Lymphoma.
|
|
Obinutuzumab Maintenance Therapy - 56 day
Regimen
|
00425a
Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment with obinutuzumab and chemotherapy (CHOP, CVP or bendamustine) or have stable disease.
|
|
Obinutuzumab and Bendamustine Therapy
Regimen
|
00424a
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
00424b
Obinutuzumab in combination with bendamustine is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
|
|
Obinutuzumab cycloPHOSphamide VinCRIStine and PrednisoLONE (O- CVP) Therapy– 21 days
Regimen
|
00550a
Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
|
|
Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (O-CHOP) Therapy – 21 day
Regimen
|
00549a
Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.
|
|
Pembrolizumab 200mg Monotherapy
Regimen
|
00455i
As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
|
|
Pembrolizumab 400mg monotherapy
Regimen
|
00558i
As monotherapy for the treatment of adult patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.
|
|
Pixantrone Therapy
Regimen
|
00255a
Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell Lymphomas (NHL).
The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy.
|
|
Plerixafor and G-CSF Therapy
Regimen
|
00536a
Is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma and multiple myeloma whose cells mobilise poorly
|
|
Polatuzumab Vedotin, Bendamustine and riTUXimab Therapy
Regimen
|
00685a
Polatuzumab Vedotin in combination with bendamustine and riTUXimab for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
|
|
Polatuzumab Vedotin, riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE Therapy
Regimen
|
00833a
Polatuzumab Vedotin in combination with riTUXimab, cycloPHOSphamide, DOXOrubicin and prednisoLONE for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL)
|
|
riTUXimab, Methotrexate, Procarbazine and vinCRIStine (R-MPV) – 14 Days Induction Therapy
Regimen
|
00664a
Treatment of newly diagnosed primary CNS lymphoma (PCNSL)
|
|
High Dose Cytarabine Consolidation Therapy (post RMPV) - 28 day Therapy
Regimen
|
00666a
Consolidation chemotherapy for the treatment of patients with newly diagnosed primary CNS lymphoma (PCNSL)
|
|
riTUXimab 375 mg/m2 Maintenance Therapy-84 day
Regimen
|
00540a
Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell non-Hodgkin's Lymphoma (NHL) in patients who have responded to induction therapy
|
|
riTUXimab 375 mg/m2 Therapy-7 day
Regimen
|
00541a
First line treatment of follicular lymphoma
00541b
As monotherapy for induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy
00541c
As monotherapy for retreatment of patients who have responded to previous treatment with riTUXimab monotherapy for relapsed/refractory follicular lymphoma,
|
|
riTUXimab 375 mg/m2 Combination Therapy-21 day
Regimen
|
00542a
In combination with chemotherapy for induction treatment of
previously untreated or relapsed/ refractory CD 20 positive patients with follicular lymphoma
|
|
riTUXimab 375 mg/m2 Maintenance Therapy- 56 day
Regimen
|
00543a
Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell non-Hodgkin Lymphoma patients responding to induction therapy
|
|
RiTUXimab (S/C 1400mg) Maintenance Therapy-84 day
Regimen
|
00599a
Maintenance therapy for the treatment of relapsed/refractory follicular CD20 positive, B-cell non-Hodgkin's lymphoma (NHL) in patients who have responded to induction therapy.
|
|
RiTUXimab (S/C 1400mg) Maintenance Therapy- 56 day
Regimen
|
00600a
Maintenance therapy for the treatment of previously untreated follicular CD20 positive, B-cell non-Hodgkin's lymphoma patients responding to induction therapy.
|
|
riTUXimab and Bendamustine Therapy
Regimen
|
00345a
Treatment of patients with previously untreated indolent CD20-positive, stage III-IV non-Hodgkin's lymphoma (NHL).
00345b
Treatment of patients with previously untreated CD20-positive, stage III-IV mantle cell lymphoma (MCL), ineligible for autologous stem cell transplant.
|
|
R-CEOP Therapy
Regimen
|
00510a
Treatment of non-Hodgkin's CD20 positive lymphoma for patients not suitable for anthracycline therapy
|
|
(*riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRIStine and Prednisolone (*R)-CHOP Therapy– 14 days
Regimen
|
00409a
Treatment of non-Hodgkin's Lymphoma (NHL)*
*Rituximab to be included in CD20 positive patients
|
|
(*riTUXimab) cycloPHOSphamide, DOXOrubicin, VinCRIStine and prednisoLONE (*R)-CHOP) Therapy– 21 days
Regimen
|
00307a
Treatment of non-Hodgkin's lymphoma (NHL).*
*riTUXimab to be included in CD20 positive patients.
|
|
riTUXimab S/C, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (R-CHOP) Therapy – 21 Days
Regimen
|
00667a
Treatment of non-Hodgkin’s lymphoma (NHL)
|
|
(R**)- miniCHOP Therapy – 21 days
Regimen
|
00436a
Treatment of non-Hodgkin's lymphoma in patients aged greater than 80 or with significant co-morbidities.
* riTUXimab to be included in all CD20 positive patients.
|
|
R-CODOX-M Therapy Patients less than or equal to 65 years
Regimen
|
00398a
Treatment of Burkitt Lymphoma in patients less than or equal to 65 years.
|
|
(R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient
Regimen
|
00751a
Treatment of relapsed/refractory non-Hodgkin’s lymphoma (NHL)*
00751b
Treatment of relapsed/refractory Hodgkin’s lymphoma (HL)
|
|
R-CODOX-M Therapy Patients greater than 65 years
Regimen
|
00403a
Treatment of Burkitt Lymphoma in patients aged greater than 65 years.
|
|
(R**)-DHAP Therapy
Regimen
|
00395a
Treatment of relapsed non-Hodgkin's Lymphoma**
**Rituximab to be included in CD20 positive patients
00395b
Treatment of relapsed Hodgkins Lymphoma
|
|
(R**)-ESHAP Therapy
Regimen
|
00394a
Treatment of relapsed non-Hodgkin's lymphoma
00394b
Treatment of relapsed Hodgkins Lymphoma
|
|
riTUXimab** Gemcitabine and CISplatin ((R**)-GDP) Therapy
Regimen
|
00441a
Treatment of relapsed non-Hodgkin's Lymphoma
00441b
Treatment of relapsed Hodgkin’s Lymphoma
|
|
R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy[i] - 14 day
Regimen
|
00506a
Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem cell transplant.
|
|
riTUXimab-Hyper CVAD Therapy (MCL)-Part A
Regimen
|
00466a
Treatment of adult patients with mantle cell lymphoma
|
|
riTUXimab-Methotrexate and Cytarabine Therapy (MCL)-Hyper CVAD Part B
Regimen
|
00467a
Treatment of adult patients with mantle cell lymphoma
|
|
(R**)-ICE ((RiTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy
Regimen
|
00397a
Treatment of relapsed/refractory non-Hodgkin’s Lymphoma**
**Rituximab to be included in CD20 positive patients.
00397b
Treatment of relapsed/refractory Hodgkin’s Lymphoma.
|
|
ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy
Regimen
|
00842a
Treatment of relapsed/refractory non-Hodgkin’s Lymphoma
00842b
Treatment of relapsed/refractory Hodgkin’s Lymphoma
|
|
R-IVAC Therapy Patients less than or equal to 65 years
Regimen
|
00399a
Treatment of patients with extensive stage Burkitt Lymphoma aged less than or equal to 65 years.
|
|
R-IVAC Therapy Patients greater than 65 years
Regimen
|
00404a
Treatment of patients with extensive Burkitt Lymphoma aged greater than 65 years.
|
|
(*riTUXimab) Cyclophosphamide and PrednisoLONE (R*)-CVP ) Therapy-21 days
Regimen
|
00293a
First line treatment for patients with stage 3/4 follicular lymphoma
00293b
Treatment of patients with relapsed/refractory low grade B cell non-Hodgkin’s lymphoma (NHL)*
*Rituximab to be included in CD20 positive patients.
|
|
(*riTUXimab)-Gemcitabine Cyclophosphamide vinCRIStine and PrednisoLONE (*R)-GCVP) Therapy–21 days
Regimen
|
00737a
Treatment of high-grade non-Hodgkin Lymphoma in patients who are unsuitable for R-CHOP due to impaired cardiac function or other comorbidities*
*riTUXimab to be included in CD20 positive patients
|
|
Siltuximab Monotherapy
Regimen
|
00277a
Treatment of adult patients with Multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus 8 (HHV-8) negative.
|
|
SMILE Therapy (NK or T cell Lymphoma)
Regimen
|
00407a
Newly diagnosed stage II- IV or relapsed/refractory extranodal natural killer/T-cell lymphoma
|
|
Zanubrutinib Therapy
Regimen
|
00708a
As monotherapy for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM), who have received at least one prior therapy or as first line treatment for patients unsuitable for chemo-immunotherapy
708b
As monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), who are treatment naïve and have del(17p) and/or TP53-mutated disease
708c
As monotherapy for the treatment of adult patients with CLL, who have relapsed and/or refractory disease following at least one line of prior therapy
|
